Erta Kalanxhi - Search Results

Year	Number of Results
2007	1
2009	1
2011	2
2012	3
2014	2
2016	3
2017	1
2018	1
2019	1
2020	2
2021	2
2022	0

1

Confidence interval methods for antimicrobial resistance surveillance data.

Kalanxhi E, Osena G, Kapoor G, Klein E. Kalanxhi E, et al. Antimicrob Resist Infect Control. 2021 Jun 9;10(1):91. doi: 10.1186/s13756-021-00960-5. Antimicrob Resist Infect Control. 2021. PMID: 34108041 Free PMC article.

2

Immune-Modulating Effects of Conventional Therapies in Colorectal Cancer.

Kalanxhi E, Meltzer S, Ree AH. Kalanxhi E, et al. Cancers (Basel). 2020 Aug 6;12(8):2193. doi: 10.3390/cancers12082193. Cancers (Basel). 2020. PMID: 32781554 Free PMC article. Review.

3

Modelling COVID-19 transmission in Africa: countrywise projections of total and severe infections under different lockdown scenarios.

Frost I, Craig J, Osena G, Hauck S, Kalanxhi E, Schueller E, Gatalo O, Yang Y, Tseng KK, Lin G, Klein E. Frost I, et al. Among authors: kalanxhi e. BMJ Open. 2021 Mar 8;11(3):e044149. doi: 10.1136/bmjopen-2020-044149. BMJ Open. 2021. PMID: 34006031 Free PMC article.

4

Biomarkers of treatment toxicity in combined-modality cancer therapies with radiation and systemic drugs: study design, multiplex methods, molecular networks.

Ree AH, Meltzer S, Flatmark K, Dueland S, Kalanxhi E. Ree AH, et al. Among authors: kalanxhi e. Int J Mol Sci. 2014 Dec 9;15(12):22835-56. doi: 10.3390/ijms151222835. Int J Mol Sci. 2014. PMID: 25501337 Free PMC article. Review.

5

Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer.

Meltzer S, Bjørnetrø T, Lyckander LG, Flatmark K, Dueland S, Samiappan R, Johansen C, Kalanxhi E, Ree AH, Redalen KR. Meltzer S, et al. Among authors: kalanxhi e. Transl Oncol. 2019 Aug;12(8):1038-1044. doi: 10.1016/j.tranon.2019.04.014. Epub 2019 May 27. Transl Oncol. 2019. PMID: 31146167 Free PMC article.

6

Corrigendum to "Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer" [Transl Oncol 12 (8) (2019) 1038-1044].

Meltzer S, Bjørnetrø T, Lyckander LG, Flatmark K, Dueland S, Samiappan R, Johansen C, Kalanxhi E, Ree AH, Redalen KR. Meltzer S, et al. Among authors: kalanxhi e. Transl Oncol. 2020 Jan;13(1):122-124. doi: 10.1016/j.tranon.2019.09.005. Transl Oncol. 2020. PMID: 31843135 Free PMC article. No abstract available.

7

Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer.

Kalanxhi E, Meltzer S, Schou JV, Larsen FO, Dueland S, Flatmark K, Jensen BV, Hole KH, Seierstad T, Redalen KR, Nielsen DL, Ree AH. Kalanxhi E, et al. Br J Cancer. 2018 May;118(10):1322-1328. doi: 10.1038/s41416-018-0085-y. Epub 2018 Apr 26. Br J Cancer. 2018. PMID: 29695770 Free PMC article.

8

The role of serotonin and p53 status in the radiation-induced bystander effect.

Kalanxhi E, Dahle J. Kalanxhi E, et al. Int J Radiat Biol. 2012 Oct;88(10):773-6. doi: 10.3109/09553002.2012.711919. Epub 2012 Aug 2. Int J Radiat Biol. 2012. PMID: 22803606

9

Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening.

Kalanxhi E, Hektoen HH, Meltzer S, Dueland S, Flatmark K, Ree AH. Kalanxhi E, et al. BMC Cancer. 2016 Jul 26;16:536. doi: 10.1186/s12885-016-2601-x. BMC Cancer. 2016. PMID: 27461255 Free PMC article. Clinical Trial.

10

Transcriptional responses in irradiated and bystander fibroblasts after low dose α-particle radiation.

Kalanxhi E, Dahle J. Kalanxhi E, et al. Int J Radiat Biol. 2012 Oct;88(10):713-9. doi: 10.3109/09553002.2012.704657. Epub 2012 Jul 18. Int J Radiat Biol. 2012. PMID: 22765265

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results